A detailed history of American Portfolios Advisors transactions in Gt Biopharma, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 14 shares of GTBP stock, worth $41. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Holding current value
$41
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$1.81 - $56.1 $25 - $785
14 New
14 $25,000

Others Institutions Holding GTBP

About GT Biopharma, Inc.


  • Ticker GTBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,557,700
  • Market Cap $96M
  • Description
  • GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...
More about GTBP
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.